Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)

Abstract

The ERK/MAP kinase cascade is a key mechanism subject to dysregulation in cancer and is constitutively activated or highly upregulated in many tumor types. Mutations associated with upstream pathway components RAS and Raf occur frequently and contribute to the oncogenic phenotype through activation of MEK and then ERK. Inhibitors of MEK have been shown to effectively block upregulated ERK/MAPK signaling in a range of cancer cell lines and have further demonstrated early evidence of efficacy in the clinic for the treatment of cancer. Guided by structural insight, a strategy aimed at the identification of an optimal diphenylamine-based MEK inhibitor with an improved metabolism and safety profile versus PD-0325901 led to the discovery of development candidate 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S)-piperidin-2-yl]azetidin-3-ol (XL518, GDC-0973) (1). XL518 exhibits robust in vitro and in vivo potency and efficacy in preclinical models with sustained duration of action and is currently in early stage clinical trials. KEYWORDS: MAPK pathway, MEK, cancer, kinase inhibitor, XL518, GDC-0973 T he MAPK cascade, or mitogen-activated protein kinase signal transduction pathway, is a mechanism commonly subject to dysregulation in cancer, and constitutive or highly upregulated signaling is a frequent hallmark of oncogenic transformation and progression. Controlled by activation of RAS at the cell surface interior, the subsequent stimulation of Raf and then MEK and ERK serves to regulate a range of key intracellular effectors associated with cell proliferation, 1 invasion, 2 angiogenesis, 3 and apoptotic resistance. 4 Mutated RAS is associated with almost one-third of human cancers, and a majority of malignant melanomas and papillary thyroid cancers harbor B-Raf mutations. 5,6 Inhibitors of MEK have demonstrated efficacy against malignant tumors characterized by mutations in either RAS or Raf in preclinical models, and early development candidates including GSK1120212, In some tumors, activation of both the RAS driven ERK/ MAPK cascade and the PI3K-Akt pathway is observed, resulting in degenerate and convergent oncogenic signals, and upregulation or constitutive PI3K pathway activation is associated with resistance to MEK inhibitor single agent treatment.10 Several combination approaches using inhibitors of mTor, PI3K, Akt, and Raf have more recently been validated in preclinical models and are being pursued clinically. Herein, the discovery of XL518 (GDC-0973) (1), a potent and selective MEK inhibitor, is described. XL518 is currently in early stage clinical testing as both a single agent and in combination with the class I PI3K inhibitor GDC-0941. 11Our goal at the outset was the identification of a potent and selective MEK inhibitor with sustained duration of efficacy suitable for qd dosing and an optimized safety profile relative to clinical precursors. The diphenylamine series disclosed by the Pfizer/Warner Lambert groups served as a starting point for our effort. A key aspect tha...

PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF-Mutated Melanoma

“…3A & S3A) (32). Importantly, the combined use of these agents elicited robust suppression of pAKT and pERK, as well as more robust suppression of pRPS6 and p4EB-P1 than that achieved with either single agent alone.…”

Cobimetinib: First Global Approval

“…Results from an animal study imply that cobimetinib has higher concentrations in the tumor than in plasma and the brain [11], and that it remains in the tumor longer than in plasma [19].…”

“…In vitro, the 50 % maximum inhibitory concentration for MEK1 was 0.9 nmol/L [11]. In vitro trials in MAPK-dysregulated cancer cells showed that cobimetinib is associated with inhibition of ERK1/2 phosphorylation; ERK1/2 activity is a key component of the MAPK pathway [5].…”

“…Thus, cobimetinib is associated with inhibition of the dysregulated MAPK pathway effects (induced cell cycle progression, cell proliferation, cell survival and cell migration) [5]. Inhibition of ERK activity was considerably greater in the tumor than in the brain, in animal models [11].…”

Cobimetinib Plus Vemurafenib: A Review in BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

“…3.3) led to the hypothesis that targeting multiple points on the MAPK pathway may enhance antitumour activity [2]. Cobimetinib is a potent, highly selective, reversible inhibitor of MEK1 and MEK2 [3,11,12]. Cobimetinib potently inhibited phosphorylation of ERK in two murine xenograft models of BRAF V600 -mutated melanoma (melanoma cells harboured a BRAF V600D mutation and were PTEN deficient in one xenograft model and harboured a BRAF V600E mutation in the other xenograft model) [13].…”